Xylazine Overdoses On the Rise
Introduction
The increasing prevalence of fatal overdoses involving the veterinary sedative Xylazine, popularly known as the "Zombie Drug," is a pressing concern in Connecticut's drug market. Understanding the risks associated with Xylazine is crucial due to its potential severe health consequences. To delve deeper into this issue, watch the news clip below featuring our UNCAS Mobile Health Team addressing the Xylazine epidemic.
Narcan Resistance
It's vital to note that Xylazine exhibits resistance to Narcan, rendering the standard Narcan reversal procedure ineffective in case of an overdose.
About Xylazine
Nature and Usage
Xylazine, classified as a veterinary tranquilizer by the National Institute on Drug Abuse (NIDA), lacks approval for human use.
Overdose Crisis Link
Increasingly associated with overdose deaths in the ongoing drug addiction crisis, especially when combined with illicit fentanyl.
Patterns of Use
Research indicates a trend of concurrent use with illicit fentanyl, knowingly or unknowingly, enhancing euphoric effects.
Nationwide Impact
Increased Deaths
Statistics reveal a significant surge in overdose deaths involving Xylazine nationwide, particularly impacting the Northeast.
Regional Statistics
Notably, Pennsylvania witnessed a drastic rise from 2% to 26% in drug overdose deaths involving Xylazine between 2015 and 2020.
Connecticut Impact
In 2020, Xylazine contributed to 10% of drug overdose deaths in Connecticut.
Multi-Substance Involvement
Combination with Other Drugs
Most fatalities linked to Xylazine and fentanyl also involved additional substances such as cocaine, heroin, benzodiazepines, alcohol, gabapentin, methadone, and prescription opioids.